Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Alzheimer Disease HELP
Based on 41,736 articles published since 2009
|||| 16 

These are the 41736 published articles about Alzheimer Disease that originated from Worldwide during 2009-2019.
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline [Investigation of Genetic Etiology in Neurodegenerative Dementias: Recommendations from the Centro Hospitalar São João Neurogenetics Group]. 2016

Massano, João / Leão, Miguel / Garrett, Carolina / Anonymous630894. ·Departamento de Neurociências Clínicas e Saúde Mental. Faculdade de Medicina. Universidade do Porto. Porto. Portugal; Serviço de Neurologia. Hospital Pedro Hispano. Unidade Local de Saúde de Matosinhos. Matosinhos. Portugal. · Serviço de Genética. Faculdade de Medicina. Universidade do Porto. Porto. Portugal; Unidade de Neuropediatria. Serviço de Pediatria. Centro Hospitalar São João. Porto. Portugal. · Departamento de Neurociências Clínicas e Saúde Mental. Faculdade de Medicina. Universidade do Porto. Porto. Portugal; Serviço de Neurologia. Centro Hospitalar São João. Porto. Portugal. ·Acta Med Port · Pubmed #28103467.

ABSTRACT: In the past few years several gene mutations have been identified as causative of the most frequent neurodegenerative dementias (Alzheimer disease and frontotemporal dementia). These advances, along with the complex phenotype-genotype relationships and the costs associated with genetic testing, have often made it difficult for clinicians to decide with regard to a rational plan for the investigation of the genetic etiology of the degenerative dementias. The Centro Hospitalar São João Neurogenetics Group, a multidisciplinary team of Neurologists and Geneticists with special interest in neurogenetic disorders, devised consensus recommendations for the investigation of the genetic etiology of Alzheimer disease and frontotemporal dementia in clinical practice, based on international consensus documents (currently containing partly outdated information) and published scientific evidence on this topic. Alzheimer disease may be caused by mutations in PSEN1, PSEN2 and APP. APOE genotyping is not recommended for the diagnostic or genetic counseling purposes in Alzheimer disease. Frontotemporal dementia may be caused by mutations in several genes such as c9orf72, PGRN, MAPT, TBK1, VCP, SQSTM1, and UBQLN2. This paper pragmatically approaches the process of genetic diagnosis in Alzheimer disease and frontotemporal dementia, with specific recommendations for both disorders.

2 Guideline Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus. 2015

Arbizu, Javier / García-Ribas, Guillermo / Carrió, Ignasi / Garrastachu, Puy / Martínez-Lage, Pablo / Molinuevo, José Luis. ·Servicio de Medicina Nuclear, Clínica Universidad de Navarra, Pamplona, España. Electronic address: jarbizu@unav.es. · Servicio de Neurología, Hospital Universitario Ramón y Cajal, Madrid, España. · Servicio de Medicina Nuclear, Hospital de la Santa Creu i Sant Pau, Barcelona, España. · Servicio de Medicina Nuclear, Hospital San Pedro y Centro de Investigación Biomédica de La Rioja (CIBIR), Logroño, España. · Neurología Fundación CITA-Alzhéimer Fundazioa, Centro de Investigación y Terapias Avanzadas, San Sebastián, España. · Unidad de Enfermedad de Alzheimer y Otros Trastornos Cognitivos, Servicio de Neurología, Hospital Clinic i Universitari ICN y Fundación Pasqual Maragall, Barcelona, España. ·Rev Esp Med Nucl Imagen Mol · Pubmed #26099942.

ABSTRACT: The new diagnostic criteria for Alzheimer's disease (AD) acknowledges the interest given to biomarkers to improve the specificity in subjects with dementia and to facilitate an early diagnosis of the pathophysiological process of AD in the prodromal or pre-dementia stage. The current availability of PET imaging biomarkers of synaptic dysfunction (PET-FDG) and beta amyloid deposition using amyloid-PET provides clinicians with the opportunity to apply the new criteria and improve diagnostic accuracy in their clinical practice. Therefore, it seems essential for the scientific societies involved to use the new clinical diagnostic support tools to establish clear, evidence-based and agreed set of recommendations for their appropriate use. The present work includes a systematic review of the literature on the utility of FDG-PET and amyloid-PET for the diagnosis of AD and related neurodegenerative diseases that occur with dementia. Thus, we propose a series of recommendations agreed on by the Spanish Society of Nuclear Medicine and Spanish Society of Neurology as a consensus statement on the appropriate use of PET imaging biomarkers.

3 Guideline A practical guideline for intracranial volume estimation in patients with Alzheimer's disease. 2015

Sargolzaei, Saman / Sargolzaei, Arman / Cabrerizo, Mercedes / Chen, Gang / Goryawala, Mohammed / Noei, Shirin / Zhou, Qi / Duara, Ranjan / Barker, Warren / Adjouadi, Malek. · ·BMC Bioinformatics · Pubmed #25953026.

ABSTRACT: BACKGROUND: Intracranial volume (ICV) is an important normalization measure used in morphometric analyses to correct for head size in studies of Alzheimer Disease (AD). Inaccurate ICV estimation could introduce bias in the outcome. The current study provides a decision aid in defining protocols for ICV estimation in patients with Alzheimer disease in terms of sampling frequencies that can be optimally used on the volumetric MRI data, and the type of software most suitable for use in estimating the ICV measure. METHODS: Two groups of 22 subjects are considered, including adult controls (AC) and patients with Alzheimer Disease (AD). Reference measurements were calculated for each subject by manually tracing intracranial cavity by the means of visual inspection. The reliability of reference measurements were assured through intra- and inter- variation analyses. Three publicly well-known software packages (Freesurfer, FSL, and SPM) were examined in their ability to automatically estimate ICV across the groups. RESULTS: Analysis of the results supported the significant effect of estimation method, gender, cognitive condition of the subject and the interaction among method and cognitive condition factors in the measured ICV. Results on sub-sampling studies with a 95% confidence showed that in order to keep the accuracy of the interleaved slice sampling protocol above 99%, the sampling period cannot exceed 20 millimeters for AC and 15 millimeters for AD. Freesurfer showed promising estimates for both adult groups. However SPM showed more consistency in its ICV estimation over the different phases of the study. CONCLUSIONS: This study emphasized the importance in selecting the appropriate protocol, the choice of the sampling period in the manual estimation of ICV and selection of suitable software for the automated estimation of ICV. The current study serves as an initial framework for establishing an appropriate protocol in both manual and automatic ICV estimations with different subject populations.

4 Guideline Diabetes and dementia in older people: a Best Clinical Practice Statement by a multidisciplinary National Expert Working Group. 2014

Sinclair, A J / Hillson, R / Bayer, A J / Anonymous4140803. ·Institute of Diabetyes for Older People (IDOP), University of Bedfordshire, Luton. ·Diabet Med · Pubmed #25131194.

ABSTRACT: Both dementia and diabetes mellitus are long-term disabling conditions and each may be a co-morbidity of the other. Type 2 diabetes is associated with a 1.5- to 2-fold higher risk of dementia. Diabetes also may occur for the first time in many individuals with mental ill health, including cognitive impairment and dementia, and this may complicate management and lead to difficulties in self-care. Case finding is often poor for cognitive impairment in medical settings and for diabetes in mental health settings and this needs to be addressed in the development of care pathways for both conditions. Many other deficiencies in quality care (both for dementia and diabetes) currently exist, but we hope that this Best Clinical Practice Statement will provide a platform for further work in this area. We have outlined the key steps in an integrated care pathway for both elements of this clinical relationship, produced guidance on identifying each condition, dealt with the potentially hazardous issue of hypoglycaemia, and have outlined important competencies required of healthcare workers in both medical/diabetes and mental health settings to enhance clinical care.

5 Guideline Recommendations of the Alzheimer's disease-related dementias conference. 2014

Montine, Thomas J / Koroshetz, Walter J / Babcock, Debra / Dickson, Dennis W / Galpern, Wendy R / Glymour, M Maria / Greenberg, Steven M / Hutton, Michael L / Knopman, David S / Kuzmichev, Andrey N / Manly, Jennifer J / Marder, Karen S / Miller, Bruce L / Phelps, Creighton H / Seeley, William W / Sieber, Beth-Anne / Silverberg, Nina B / Sutherland, Margaret / Torborg, Christine L / Waddy, Salina P / Zlokovic, Berislav V / Corriveau, Roderick A / Anonymous800802. ·From the Department of Pathology (T.J.M.), University of Washington, Seattle · National Institute of Neurological Disorders and Stroke (W.J.K., D.B., W.R.G., A.N.K., B.-A.S., M.S., C.L.T., S.P.W., R.A.C.), Bethesda, MD · Neuropathology Lab (D.W.D.), Mayo Clinic, Jacksonville, FL · Department of Epidemiology & Biostatistics (M.M.G.), University of California San Francisco · Hemorrhagic Stroke Research Program (S.M.G.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA · Neurodegenerative Diseases DHT at Eli Lilly and Company (M.L.H.), Lilly Research Center, Windlesham, UK · Department of Neurology (D.S.K.), Mayo Clinic Rochester, MN · Taub Institute for Research on Alzheimer's Disease and the Aging Brain (J.J.M., K.S.M.), Columbia University Medical Center, New York · Columbia University (J.J.M., K.S.M.), College of Physicians and Surgeons, New York, NY · University of California San Francisco Memory and Aging Center (B.L.M., W.W.S.) · National Institute on Aging (C.H.P., N.B.S.), Bethesda, MD · and Zilhka Neurogenetic Institute (B.V.Z.), Center for Neurodegeneration and Regeneration and Department of Physiology and Biophysics, University of Southern California, Keck School of Medicine, Los Angeles, CA. ·Neurology · Pubmed #25080517.

ABSTRACT: The National Alzheimer's Project Act, signed into law in 2011, mandates a National Plan to Address Alzheimer's Disease that is updated annually. In the Plan, the term Alzheimer disease includes not only Alzheimer disease (AD) proper, but also several specified related dementias, namely, frontotemporal, Lewy body, vascular, and mixed dementia. In response to a specific action item in the 2012 National Plan, the National Institute of Neurological Disorders and Stroke, in collaboration with the National Institute on Aging, convened panels of experts and conducted a 2-day public conference to develop research priorities and timelines for addressing Alzheimer disease-related dementias (ADRD) in 5 topic areas: multiple etiology dementias, health disparities, Lewy body dementias including dementia with Lewy bodies and Parkinson disease dementia, frontotemporal dementia and related tauopathies, and vascular contributions to ADRD. By design, the product was up to 8 prioritized research recommendations in each topic area including estimated timelines from when work on a recommendation is started to completion or to full implementation of an ongoing activity, and recognition of shared research themes across recommendations. These included increased education and training of both researchers and health care professionals, addressing health disparities, fundamental neurobiology research, advanced diagnostics, collaborative biosample repositories, and a focus on developing effective interventions to prevent or treat ADRD by the year 2025 as targeted by the National Plan.

6 Guideline Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia: recommendations for family physicians. 2014

Moore, Ainsley / Patterson, Christopher / Lee, Linda / Vedel, Isabelle / Bergman, Howard / Anonymous2070794. ·Associate Professor in the Department of Family Medicine at McMaster University in Hamilton, Ont. amoore@mcmaster.ca. · Professor in the Division of Geriatric Medicine of the Department of Medicine at McMaster University. · Associate Clinical Professor in the Department of Family Medicine at McMaster University. · Assistant Professor in the Division of Geriatrics of the Department of Family Medicine at McGill University in Montreal, Que. · Chair of the Department of Family Medicine, Professor of Family Medicine in the Department of Medicine and Oncology, and Dr Joseph Kaufmann Professor of Geriatric Medicine at McGill University. ·Can Fam Physician · Pubmed #24829003.

ABSTRACT: OBJECTIVE: To revise diagnostic strategies for Alzheimer disease (AD), update recommendations on symptomatic treatment of dementia, and provide an approach to rapidly progressive and early-onset dementias. COMPOSITION OF THE COMMITTEE: Experts and delegates representing relevant disciplines from diverse regions across Canada discussed and agreed upon revisions to the 2006 guidelines. METHODS: The GRADE (grading of recommendations, assessment, development, and evaluation) system was used to evaluate consensus on recommendations, which was defined as when 80% or more of participants voted for the recommendation. Evidence grades are reported where possible. REPORT: Important for FPs, despite advances in liquid biomarkers and neuroimaging, the diagnosis of dementia in Canada remains fundamentally clinical. New core clinical criteria for the diagnosis of AD now recognize less common, non-amnestic forms. Early-onset dementia, a rare but important condition, should prompt referral to specialists with access to genetic counselors. Rapidly progressive dementia, poorly defined in the literature, is described to facilitate detection of this rare but important condition. There are new expanded indications for cholinesterase inhibitors beyond AD, as well as guidelines for their discontinuation, which had not been previously described. New evidence regarding use of memantine, antidepressants, and other psychotropic medications in dementia care is presented. CONCLUSION: Several recommendations from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia are relevant to FPs. For guidelines to remain useful, family physicians should participate in all stages of the ongoing development process, including topic selection.

7 Guideline An assessment by the Statin Cognitive Safety Task Force: 2014 update. 2014

Rojas-Fernandez, Carlos H / Goldstein, Larry B / Levey, Allan I / Taylor, Beth A / Bittner, Vera / The National Lipid Association's Safety Task Force, ?. ·Schlegel-UW Research Institute for Ageing; School of Public Health and Health Systems; School of Pharmacy, University of Waterloo, 10 Victoria Street S, Room 7004, Kitchener, Ontario N2G 1C5, Canada; Michael G. DeGroote School of Medicine, Department of Family Medicine, McMaster University, University of Waterloo, Hamilton, ON, Canada. Electronic address: carlos.rojas-fernandez@uwaterloo.ca. · Duke Stroke Center, Duke University and Durham VAMC, Durham, NC. · Department of Neurology, Emory University, Atlanta, GA. · Department of Preventive Cardiology, Hartford Hospital & University of Hartford, Hartford, CT. · Division of Cardiovascular Disease, Preventive Cardiology Section, University of Alabama at Birmingham, Birmingham, AL. ·J Clin Lipidol · Pubmed #24793442.

ABSTRACT: The National Lipid Association's Safety Task Force convened a consensus conference of experts to develop a position statement on cognitive function to revise and update that published originally by the Association in the 2006 assessment of statin safety by a panel of neurologists. The current expert panel was charged with addressing the specific issue of potential adverse cognitive effects attributable to statins. Search strategies recently used in systematic reviews were used to identify relevant evidence using keywords and topics via Medline searches from 1966 to December 2013. Manual searches of bibliographies were also conducted. Panel members were asked to use the evidence to formulate answers to a series of questions of relevance to the subject matter. The strength of recommendations and quality of evidence were graded using accepted contemporary definitions and procedures. Recommendations to patients, health professionals, and researchers were put forth by the panel to aid in daily clinical decision making, and in future research endeavors.

8 Guideline Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging. 2013

Johnson, Keith A / Minoshima, Satoshi / Bohnen, Nicolaas I / Donohoe, Kevin J / Foster, Norman L / Herscovitch, Peter / Karlawish, Jason H / Rowe, Christopher C / Hedrick, Saima / Pappas, Virginia / Carrillo, Maria C / Hartley, Dean M / Anonymous4140762. ·Departments of Radiology and Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. ·Alzheimers Dement · Pubmed #23809369.

ABSTRACT: Amyloid PET imaging is a novel diagnostic test that can detect in living humans one of the two defining pathologic lesions of Alzheimer disease, amyloid-β deposition in the brain. The Amyloid Imaging Task Force of the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging previously published appropriate use criteria for amyloid PET as an important tool for increasing the certainty of a diagnosis of Alzheimer disease in specific patient populations. Here, the task force further clarifies and expands 3 topics discussed in the original paper: first, defining dementia experts and their use of proper documentation to demonstrate the medical necessity of an amyloid PET scan; second, identifying a specific subset of individuals with mild cognitive impairment for whom an amyloid PET scan is appropriate; and finally, developing educational programs to increase awareness of the amyloid PET appropriate use criteria and providing instructions on how this test should be used in the clinical decision-making process.

9 Guideline Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. 2013

Johnson, Keith A / Minoshima, Satoshi / Bohnen, Nicolaas I / Donohoe, Kevin J / Foster, Norman L / Herscovitch, Peter / Karlawish, Jason H / Rowe, Christopher C / Carrillo, Maria C / Hartley, Dean M / Hedrick, Saima / Pappas, Virginia / Thies, William H / Anonymous4420748 / Anonymous4430748 / Anonymous4440748. ·Departments of Radiology and Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA ·Alzheimers Dement · Pubmed #23360977.

ABSTRACT: Positron emission tomography (PET) of brain amyloid b is a technology that is becoming more available, but its clinical utility in medical practice requires careful definition. To provide guidance to dementia care practitioners, patients, and caregivers, the Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging convened the Amyloid Imaging Taskforce (AIT). The AIT considered a broad range of specific clinical scenarios in which amyloid PET could potentially be used appropriately. Peer-reviewed, published literature was searched to ascertain available evidence relevant to these scenarios, and the AIT developed a consensus of expert opinion. Although empirical evidence of impact on clinical outcomes is not yet available, a set of specific appropriate use criteria (AUC) were agreed on that define the types of patients and clinical circumstances in which amyloid PET could be used. Both appropriate and inappropriate uses were considered and formulated,and are reported and discussed here. Because both dementia care and amyloid PET technology are in active development, these AUC will require periodic reassessment. Future research directions are also outlined, including diagnostic utility and patient-centered outcomes.

10 Guideline Guidelines for management of idiopathic normal pressure hydrocephalus: second edition. 2012

Mori, Etsuro / Ishikawa, Masatsune / Kato, Takeo / Kazui, Hiroaki / Miyake, Hiroji / Miyajima, Masakazu / Nakajima, Madoka / Hashimoto, Masaaki / Kuriyama, Nagato / Tokuda, Takahiko / Ishii, Kazunari / Kaijima, Mitsunobu / Hirata, Yoshihumi / Saito, Makoto / Arai, Hajime / Anonymous311217. ·Department of Behavioral Neurology and Cognitive Neuroscience, Tohoku University Graduate School of Medicine, Sendai, Miyagi. ·Neurol Med Chir (Tokyo) · Pubmed #23183074.

ABSTRACT: Among the various disorders manifesting dementia, gait disturbance, and urinary incontinence in the elderly population, idiopathic normal pressure hydrocephalus (iNPH) is becoming of great importance. After the publication of the first edition of the Guidelines for Management of Idiopathic Normal Pressure Hydrocephalus in 2004 (the English version was published in 2008), clinical awareness of iNPH has risen dramatically, and the number of shunt surgeries has increased rapidly across Japan. Clinical and basic research on iNPH has increased significantly, and more high-level evidence has since been generated. The second edition of the Japanese Guidelines was thus published in July 2011, to provide a series of timely evidence-based recommendations related to iNPH. The revision of the Guidelines has been undertaken by a multidisciplinary expert working group of the Japanese Society of Normal Pressure Hydrocephalus in conjunction with the Japanese Ministry of Health, Labour and Welfare research project on "Studies on the epidemiology, pathophysiology, and treatment of normal pressure hydrocephalus." This English version of the second edition of the Guidelines was made to share these ideas with the international community and to promote international research on iNPH.

11 Guideline 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. 2012

Gauthier, S / Patterson, C / Chertkow, H / Gordon, M / Herrmann, N / Rockwood, K / Rosa-Neto, P / Soucy, J P / Anonymous1391435. ·McGill Center for Studies in Aging, 6825 LaSalle Blvd, Montreal, Quebec, H4H 1R3, Canada. Serge.gauthier@mcgill.ca ·Can J Neurol Sci · Pubmed #23073396.

ABSTRACT: -- No abstract --

12 Guideline [Consensus 2012--diagnosis and treatment of patients with dementia in Switzerland]. 2012

Monsch, A U / Büla, C / Hermelink, M / Kressig, R W / Martensson, B / Mosimann, U / Müri, R / Vögeli, S / von Gunten, A / Anonymous1910737. ·Memory Clinic, Akutgeriatrie, Universitätsspital Basel. Andreas.Monsch@unibas.ch ·Praxis (Bern 1994) · Pubmed #22991148.

ABSTRACT: -- No abstract --

13 Guideline EFNS task force: the use of neuroimaging in the diagnosis of dementia. 2012

Filippi, M / Agosta, F / Barkhof, F / Dubois, B / Fox, N C / Frisoni, G B / Jack, C R / Johannsen, P / Miller, B L / Nestor, P J / Scheltens, P / Sorbi, S / Teipel, S / Thompson, P M / Wahlund, L-O / Anonymous3050734. ·Neuroimaging Research Unit, Division of Neuroscience, Institute of Experimental Neurology, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy. m.filippi@hsr.it ·Eur J Neurol · Pubmed #22900895.

ABSTRACT: BACKGROUND AND PURPOSE: The European Federation of the Neurological Societies (EFNS) guidelines on the use of neuroimaging in the diagnosis and management of dementia are designed to revise and expand previous EFNS recommendations for the diagnosis and management of patients with Alzheimer's disease (AD) and to provide an overview of the evidence for the use of neuroimaging techniques in non-AD dementias, as well as general recommendations that apply to all types of dementia in clinical practice. METHODS: The task force working group reviewed evidence from original research articles, meta-analyses and systematic reviews, published before April 2012. The evidence was classified, and consensus recommendations were given and graded according to the EFNS guidance regulations. RESULTS: Structural imaging, which should be performed at least once in the diagnostic work-up of patients with cognitive impairment, serves to exclude other potentially treatable diseases, to recognize vascular lesions and to identify specific findings to help distinguish different forms of neurodegenerative types of dementia. Although typical cases of dementia may not benefit from routine functional imaging, these tools are recommended in those cases where diagnosis remains in doubt after clinical and structural imaging work-up and in particular clinical settings. Amyloid imaging is likely to find clinical utility in several fields, including the stratification of patients with mild cognitive impairment into those with and without underlying AD and the evaluation of atypical AD presentations. CONCLUSIONS: A number of recommendations and good practice points are made to improve the diagnosis of AD and other dementias.

14 Guideline EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. 2012

Sorbi, S / Hort, J / Erkinjuntti, T / Fladby, T / Gainotti, G / Gurvit, H / Nacmias, B / Pasquier, F / Popescu, B O / Rektorova, I / Religa, D / Rusina, R / Rossor, M / Schmidt, R / Stefanova, E / Warren, J D / Scheltens, P / Anonymous1560734. ·Department of Neurological and Psychiatric Sciences, University of Florence, Florence, Italy. sorbi@unifi.it ·Eur J Neurol · Pubmed #22891773.

ABSTRACT: BACKGROUND AND OBJECTIVES: The last version of the EFNS dementia guidelines is from 2007. In 2010, the revised guidelines for Alzheimer's disease (AD) were published. The current guidelines involve the revision of the dementia syndromes outside of AD, notably vascular cognitive impairment, frontotemporal lobar degeneration, dementia with Lewy bodies, corticobasal syndrome, progressive supranuclear palsy, Parkinson's disease dementia, Huntington's disease, prion diseases, normal-pressure hydrocephalus, limbic encephalitis and other toxic and metabolic disorders. The aim is to present a peer-reviewed evidence-based statement for the guidance of practice for clinical neurologists, geriatricians, psychiatrists and other specialist physicians responsible for the care of patients with dementing disorders. It represents a statement of minimum desirable standards for practice guidance. METHODS: The task force working group reviewed evidence from original research articles, meta-analyses and systematic reviews, published by June 2011. The evidence was classified (I, II, III, IV) and consensus recommendations graded (A, B, or C) according to the EFNS guidance. Where there was a lack of evidence, but clear consensus, good practice points were provided. RESULTS AND CONCLUSIONS: New recommendations and good practice points are made for clinical diagnosis, blood tests, neuropsychology, neuroimaging, electroencephalography, cerebrospinal fluid (CSF) analysis, genetic testing, disclosure of diagnosis, treatment of behavioural and psychological symptoms in dementia, legal issues, counselling and support for caregivers. All recommendations were revised as compared with the previous EFNS guidelines. The specialist neurologist together with primary care physicians play an important role in the assessment, interpretation and treatment of symptoms, disability and needs of dementia patients.

15 Guideline [Dementia guidelines: what should come to general practice--an interdisciplinary consensus of physicians in private practice]. 2012

Riepe, M W / Fellgiebel, A / Anonymous3530733. ·Klinik für Psychiatrie II, Sektion Gerontopsychiatrie, Universität Ulm. matthias.riepe@uni-ulm.de ·Dtsch Med Wochenschr · Pubmed #22869507.

ABSTRACT: BACKGROUND: Guidelines of Medical Societies aim at supporting the quality of medical care in general, and particularly in private practice. Usually, physicians in private practice are not part of the expert committees of medical societies that author guidelines. Guidelines represent a consensus appraising evidence from clinical studies on efficacy and side effects but also evaluating aspects of the health care system such as costs. Guidelines commonly do not account for regional specifics. Transfer of knowledge from guidelines to general practice, therefore, is incomplete. METHODS: We describe a consensus of neuropsychiatric and general physicians (n=12; 10 to 38 years of professional experience) on prioritization of diagnostic and therapeutic procedures for patients with Alzheimer's dementia as judged by relevance and practicability compared to the guideline of the Society for General Medicine (DEGAM-guideline No. 12) and the S3-guideline dementia of the German Society for Psychiatry, Psychotherapy and Neuropsychiatry (DGPPN). RESULTS: If patients and proxies do not oppose diagnosis, e. g. in cases of progressive impairment of memory with everyday relevance, the appropriate diagnostic procedures should be performed for every patient. Age or setting in which the patients live, in itself are no reason to limit antidementia therapy. Symptom fluctuations or decline of individual symptoms are compatible with treatment success. Clinical scales may only be used as supportive means to evaluate disease progression. CONCLUSION: Diagnosis and treatment of dementia are experienced as complex tasks by physicans in private practice. Practicing physicians need to adapt guidelines of medical societies on local and individual specifics.

16 Guideline [Pharmacological treatment of dementia: when, how and for how long. Recommendations of the Working Group on Dementia of the Catalan Society of Geriatrics and Gerontology]. 2012

Rodríguez, Daniel / Formiga, Francesc / Fort, Isabel / Robles, María José / Barranco, Elena / Cubí, Dolors / Anonymous1490727. ·Equipo de Evaluación Integral Ambulatoria de Trastornos Cognitivos y de la Conducta, Servicio de Geriatría, Hospital St. Llàtzer, Consorcio Sanitario de Terrassa, Terrassa, Barcelona, Spain. drodriguez@cst.cat ·Rev Esp Geriatr Gerontol · Pubmed #22633250.

ABSTRACT: Dementia in general--and Alzheimer's disease (AD) in particular--are bound to loom large among the most acute healthcare, social, and public health problems of the 21st century. AD shows a degenerative progression that can be slowed down--yet not halted--by today's most widely accepted specific treatments (those based on cholinesterase inhibitors as well as those using memantine). There is enough evidence to consider these treatments advisable for the mild, moderate and severe phases of the illness. However, in the final stage of the disease, a decision has to be made on whether to withdraw such treatment or not. In this paper, the Working Group on Dementia for the Catalan Society of Geriatrics and Gerontology reviews the use of these specific pharmacological treatments for AD, and, drawing on the scientific evidence thus gathered, makes a series of recommendations on when, how, and for how long, the currently existing specific pharmacological treatments should be used.

17 Guideline The CANMAT task force recommendations for the management of patients with mood disorders and comorbid medical conditions: diagnostic, assessment, and treatment principles. 2012

Ramasubbu, Rajamannar / Beaulieu, Serge / Taylor, Valerie H / Schaffer, Ayal / McIntyre, Roger S / Anonymous2370717. ·Department of Psychiatry and Clinical Neurosciences, University of Calgary, Hotchkiss Brain Institute, Calgary, Alberta, Canada. rramasub@ucalgary.ca ·Ann Clin Psychiatry · Pubmed #22303524.

ABSTRACT: BACKGROUND: Medical comorbidity is commonly encountered in individuals with major depressive disorder (MDD) and bipolar disorder (BD). The presence of medical comorbidity has diagnostic, prognostic, treatment, and etiologic implications underscoring the importance of timely detection and treatment. METHODS: A selective review of relevant articles and reviews published in English-language databases (1968 to April 2011) was conducted. Studies describing epidemiology, temporality of onset, treatment implications, and prognosis were selected for review. RESULTS: A growing body of evidence from epidemiologic, clinical, and biologic studies suggests that the relationship between medical illness and mood disorder is bidirectional in nature. It provides support for the multiplay of shared and specific etiologic factors interlinking these conditions. CONCLUSIONS: This article describes the complex interactions between medical illness and mood disorders and provides a meaningful approach to their comorbid clinical diagnosis and management.

18 Guideline National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. 2012

Montine, Thomas J / Phelps, Creighton H / Beach, Thomas G / Bigio, Eileen H / Cairns, Nigel J / Dickson, Dennis W / Duyckaerts, Charles / Frosch, Matthew P / Masliah, Eliezer / Mirra, Suzanne S / Nelson, Peter T / Schneider, Julie A / Thal, Dietmar Rudolf / Trojanowski, John Q / Vinters, Harry V / Hyman, Bradley T / Anonymous470711 / Anonymous480711. ·Department of Pathology, University of Washington School of Medicine, Box 359791, Seattle, WA 98104, USA. tmontine@uw.edu ·Acta Neuropathol · Pubmed #22101365.

ABSTRACT: We present a practical guide for the implementation of recently revised National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease (AD). Major revisions from previous consensus criteria are: (1) recognition that AD neuropathologic changes may occur in the apparent absence of cognitive impairment, (2) an "ABC" score for AD neuropathologic change that incorporates histopathologic assessments of amyloid β deposits (A), staging of neurofibrillary tangles (B), and scoring of neuritic plaques (C), and (3) more detailed approaches for assessing commonly co-morbid conditions such as Lewy body disease, vascular brain injury, hippocampal sclerosis, and TAR DNA binding protein (TDP)-43 immunoreactive inclusions. Recommendations also are made for the minimum sampling of brain, preferred staining methods with acceptable alternatives, reporting of results, and clinico-pathologic correlations.

19 Guideline Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. 2011

Goldman, Jill S / Hahn, Susan E / Catania, Jennifer Williamson / LaRusse-Eckert, Susan / Butson, Melissa Barber / Rumbaugh, Malia / Strecker, Michelle N / Roberts, J Scott / Burke, Wylie / Mayeux, Richard / Bird, Thomas / Anonymous4360694. ·Department of Neurology, Columbia University, New York, New York, USA. jg2673@columbia.edu [corrected] ·Genet Med · Pubmed #21577118.

ABSTRACT: Alzheimer disease is the most common cause of dementia. It occurs worldwide and affects all ethnic groups. The incidence of Alzheimer disease is increasing due, in part, to increased life expectancy and the aging baby boomer generation. The average lifetime risk of developing Alzheimer disease is 10-12%. This risk at least doubles with the presence of a first-degree relative with the disorder. Despite its limited utility, patients express concern over their risk and, in some instances, request testing. Furthermore, research has demonstrated that testing individuals for apolipoprotein E can be valuable and safe in certain contexts. However, because of the complicated genetic nature of the disorder, few clinicians are prepared to address the genetic risks of Alzheimer disease with their patients. Given the increased awareness in family history thanks to family history campaigns, the increasing incidence of Alzheimer disease, and the availability of direct to consumer testing, patient requests for information is increasing. This practice guideline provides clinicians with a framework for assessing their patients' genetic risk for Alzheimer disease, identifying which individuals may benefit from genetic testing, and providing the key elements of genetic counseling for AD.

20 Guideline Alzheimer's disease management guideline: update 2008. 2011

Segal-Gidan, Freddi / Cherry, Debra / Jones, Randi / Williams, Bradley / Hewett, Linda / Chodosh, Joshua / Anonymous4460693. ·University of Southern California, Keck School of Medicine, Los Angeles, CA, USA. segalgi@usc.edu ·Alzheimers Dement · Pubmed #21546322.

ABSTRACT: BACKGROUND: Frequent review and update of guidelines are necessary for them to remain current and useful for clinical practices. This second revision of the postdiagnostic management of Alzheimer's disease (AD) guideline by the California Workgroup was prompted by significant advances in knowledge about appropriate care management, including pharmacologic and nonpharmacologic approaches to treatment of the disease, accompanying behavioral problems, and functional decline. The focus remains explicitly on primary care, where the majority of it occurs for those with AD and other dementias. METHODS: In all, 40 experts in dementia care were recruited from a variety of disciplines across California. Four workgroups were created that reviewed recent research findings from a total of 569 publications since 2002. The revised Guideline incorporates 305 new references, including 11 state and federal laws, in addition to 78 references from the previous version. RESULTS: The Guideline is divided into four sections that address postdiagnostic management: (1) assessment, (2) treatment, (3) patient and family education and support, and (4) legal considerations associated with AD. Significant revisions and changes in each area and the underlying research to support the recommendations are presented in this article. New topics related to early stage and end-of-life were identified and recommendations were developed for these specific populations. CONCLUSIONS: The Guideline recommendations provide a framework to inform and improve medical care for AD by primary health care providers.

21 Guideline Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. 2011

O'Brien, John T / Burns, Alistair / Anonymous2780679. ·Institute for Ageing and Health, Newcastle University, Wolfson Research Centre, Campus for Ageing and Vitality, Newcastle upon Tyne, NE4 5PL, UK. j.t.o'brien@newcastle.ac.uk ·J Psychopharmacol · Pubmed #21088041.

ABSTRACT: The British Association for Psychopharmacology (BAP) coordinated a meeting of experts to review and revise its first (2006) Guidelines for clinical practice with anti-dementia drugs. As before, levels of evidence were rated using accepted standards which were then translated into grades of recommendation A to D, with A having the strongest evidence base (from randomized controlled trials) and D the weakest (case studies or expert opinion). Current clinical diagnostic criteria for dementia have sufficient accuracy to be applied in clinical practice (B) and brain imaging can improve diagnostic accuracy (B). Cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) are effective for mild to moderate Alzheimer's disease (A) and memantine for moderate to severe Alzheimer's disease (A). Until further evidence is available other drugs, including statins, anti-inflammatory drugs, vitamin E and Ginkgo biloba, cannot be recommended either for the treatment or prevention of Alzheimer's disease (A). Neither cholinesterase inhibitors nor memantine are effective in those with mild cognitive impairment (A). Cholinesterase inhibitors are not effective in frontotemporal dementia and may cause agitation (A), though selective serotonin reuptake inhibitors may help behavioural (but not cognitive) features (B). Cholinesterase inhibitors should be used for the treatment of people with Lewy body dementias (Parkinson's disease dementia and dementia with Lewy bodies (DLB)), especially for neuropsychiatric symptoms (A). Cholinesterase inhibitors and memantine can produce cognitive improvements in DLB (A). There is no clear evidence that any intervention can prevent or delay the onset of dementia. Although the consensus statement focuses on medication, psychological interventions can be effective in addition to pharmacotherapy, both for cognitive and non-cognitive symptoms. Many novel pharmacological approaches involving strategies to reduce amyloid and/or tau deposition are in progress. Although results of pivotal studies are awaited, results to date have been equivocal and no disease-modifying agents are either licensed or can be currently recommended for clinical use.

22 Guideline EFNS guidelines for the diagnosis and management of Alzheimer's disease. 2010

Hort, J / O'Brien, J T / Gainotti, G / Pirttila, T / Popescu, B O / Rektorova, I / Sorbi, S / Scheltens, P / Anonymous1080672. ·Memory Disorders Clinic, Deartment of Neurology, Charles University in Prague, Second Faculty of Medicine and Motol Hospital, Prague, Czech Republic. jakub.hort@seznam.cz ·Eur J Neurol · Pubmed #20831773.

ABSTRACT: BACKGROUND AND OBJECTIVES: In 2008 a task force was set up to develop a revision of the European Federation of the Neurological Societies (EFNS) guideline for the diagnosis and management of Alzheimer's disease (AD) and other disorders associated with dementia, published in early 2007. The aim of this revised international guideline was to present a peer-reviewed evidence-based statement for the guidance of practice for clinical neurologists, geriatricians, psychiatrists, and other specialist physicians responsible for the care of patients with AD. Mild cognitive impairment and non-Alzheimer dementias are not included in this guideline. METHODS: The task force working group reviewed evidence from original research articles, meta-analysis, and systematic reviews, published before May 2009. The evidence was classified and consensus recommendations graded (A, B, or C) according to the EFNS guidance. Where there was a lack of evidence, but clear consensus, good practice points were provided. RESULTS: The recommendations for clinical diagnosis, blood tests, neuropsychology, neuroimaging, electroencephalography, cerebrospinal fluid (CSF) analysis, genetic testing, disclosure of diagnosis, treatment of AD, behavioural and psychological symptoms in dementia, legal issues, counselling and support for caregivers were all revised as compared with the previous EFNS guideline. CONCLUSION: A number of new recommendations and good practice points are made, namely in CSF, neuropsychology, neuroimaging and reviewing non-evidence based therapies. The assessment, interpretation, and treatment of symptoms, disability, needs, and caregiver stress during the course of AD require the contribution of many different professionals. These professionals should adhere to these guideline to improve the diagnosis and management of AD.

23 Guideline EFNS guidelines on disease-specific CSF investigations. 2009

Deisenhammer, F / Egg, R / Giovannoni, G / Hemmer, B / Petzold, A / Sellebjerg, F / Teunissen, C / Tumani, H / Anonymous330630. ·Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria. florian.deisenhammer@i-med.ac.at ·Eur J Neurol · Pubmed #19475759.

ABSTRACT: We reviewed the literature for disease-specific markers in cerebrospinal fluid (CSF) and evaluated their diagnostic and prognostic relevance in neurological diseases. High tau protein in combination with low amyloid beta levels has a high sensitivity (80%) and specificity (90%) for Alzheimer's disease (AD) against normal aging and can predict conversion of mild cognitive impairment to AD. The detection of 14-3-3 has a high sensitivity (80-90%) and specificity (90%) for the diagnosis of CJD. Low or undetectable CSF hypocretin-1 (orexin-1) levels constitute a diagnostic biomarker for narcolepsy with cataplexy. Detection of beta-2-transferrin indicates CSF contamination in oto- and rhinorrhoe with a sensitivity of > 79% at a specificity of 95% similar to the beta-trace protein (sensitivity > 90%, specificity 100%). However, beta-trace protein is faster and cheaper to perform. Possible future biomarkers are: elevated levels of vascular endothelial growth factor are relatively sensitive (51-100%) and specific (73-100%) for leptomeningeal metastases from solid tumors and are associated with a poor prognosis in this condition. Elevated CSF neurofilament (Nf) levels probably reflect acute neuronal degeneration. The prognostic value of CSF Nf levels is highest in acute conditions such as subarachnoid hemorrhage, acute optic neuritis and neuromyelitis optica.

24 Guideline Consensus statement: First International Workshop on Anesthetics and Alzheimer's disease. 2009

Baranov, Dmitri / Bickler, Philip E / Crosby, Gregory J / Culley, Deborah J / Eckenhoff, Maryellen F / Eckenhoff, Roderic G / Hogan, Kirk J / Jevtovic-Todorovic, Vesna / Palotás, András / Perouansky, Misha / Planel, Emmanuel / Silverstein, Jeffrey H / Wei, Huafeng / Whittington, Robert A / Xie, Zhongcong / Zuo, Zhiyi / Anonymous4920626. ·Department of Anesthesiology and Critical Care, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA. ·Anesth Analg · Pubmed #19372347.

ABSTRACT: In order to review the current status of the potential relationship between anesthesia and Alzheimer's disease, a group of scientists recently met in Philadelphia for a full day of presentations and discussions. This special article represents a consensus view on the possible link between Alzheimer's disease and anesthesia and the steps required to test this more definitively.

25 Editorial Commentary for Sequential Therapy Based on Evolvement of Patterns: A New Model for Treatment of Alzheimer's Disease. 2019

Wilcock, Gordon / Neary, David. ·Department of Clinical Neuroscience, University of Oxford, Oxford, UK. · Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Salford, UK. ·Chin J Integr Med · Pubmed #31332719.

ABSTRACT: -- No abstract --